Response assessment using 68 Ga-PSMA ligand PET in patients undergoing 177 Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer

The first aim of this study was to evaluate Ga-PSMA conjugate 11 positron emission tomography (PSMA PET) parameters for assessment of response to Lu-PSMA-617 radioligand therapy (RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC). The second aim was to investigate factors...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of nuclear medicine and molecular imaging 2019-05, Vol.46 (5), p.1063
Hauptverfasser:	Grubmüller, Bernhard, Senn, Daniela, Kramer, Gero, Baltzer, Pascal, D'Andrea, David, Grubmüller, Karl Hermann, Mitterhauser, Markus, Eidherr, Harald, Haug, Alexander R, Wadsak, Wolfgang, Pfaff, Sarah, Shariat, Shahrokh F, Hacker, Marcus, Hartenbach, Markus
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Dipeptides - therapeutic use Follow-Up Studies Heterocyclic Compounds, 1-Ring - therapeutic use Humans Ligands Male Membrane Glycoproteins Neoplasm Metastasis Organometallic Compounds Positron Emission Tomography Computed Tomography Prostate-Specific Antigen - metabolism Prostatic Neoplasms, Castration-Resistant - diagnostic imaging Prostatic Neoplasms, Castration-Resistant - metabolism Prostatic Neoplasms, Castration-Resistant - pathology Prostatic Neoplasms, Castration-Resistant - radiotherapy Retrospective Studies ROC Curve Survival Analysis Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!